Increased levels of anti-glycan antibodies in patients with cystic fibrosis

European Journal of Medical Research

O Schröder³  F Behrens³  TO Wagner³  J Hausmann³  H Hirche²  J Stein¹  TO Hirche⁴ 

[1] Department of Gastroenterology, Elisabethen Hospital, Frankfurt, Germany;Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany;Department of Internal Medicine, Johann Wolfgang Goethe-University Hospital, Frankfurt, Germany;Department of Pulmonary Medicine, German Clinic for Diagnostics (DKD), Wiesbaden, Germany

关键词: ASCA;    anti-glycan antibodies;    crohn's disease;    cystic fibrosis;   

Others  :  824873
DOI  :  10.1186/2047-783X-16-9-385

 received in 2010-12-20, accepted in 2011-05-24,  发布年份 2011

【 摘 要 】

Background

The prevalence of Crohn's disease (CD) is increased in patients with cystic fibrosis (CF). Anti-Saccharomyces cerevisiae antibodies (ASCA) have been suggested as a screening tool to detect CD in CF. Recently, several new anti-glycan antibodies have been reported in CD.

Materials and methods

The sera of 119 CF patients of various age groups were prospectively screened for ASCA type IgG (gASCA), anti-laminaribioside carbohydrate IgG antibodies (ALCA), anti-chitobioside carbohydrate IgA antibodies (ACCA), and anti-mannobioside carbohydrate IgG antibodies (AMCA). The frequency of these anti-glycan antibodies was then compared in patients with CD, ulcerative colitis, rheumatoid arthritis and healthy volunteers.

Results

A significant number of CF patients were positive for gASCA (51.3% [41.6-60.6]) and up to three other anti-glycan antibodies concurrently. Serum levels of anti-glycan antibodies in CF and CD were not related to parameters of inflammation. Despite the well-documented difference in clinical course between male and female CF patients no gender difference of anti-glycan antibodies was found. In contrast, there was a significant positive correlation between anti-glycan markers and age in CF patients.

Conclusions

Our findings demonstrate for the first time the increased frequency of a panel of anti-glycan antibodies in CF and provide a link between the presence of these serological biomarkers and patient's age. Anti-glycan antibody profiling may therefore become a valuable tool in the care of patients with CF.

【 授权许可】

   
2011 I. Holzapfel Publishers

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Farrell PM: Improving the health of patients with cystic fibrosis through newborn screening. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Adv Pediatr 2000, 47:79-115.
• [2]Strong TV, Boehm K, Collins FS: Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization. J Clin Invest 1994, 93:347-354.
• [3]Eggermont E: Gastrointestinal manifestations in cystic fibrosis. Eur J Gastroenterol Hepatol 1996, 8:731-738.
• [4]Wilschanski M: Patterns of gastrointestinal disease associated with mutations of CFTR. Curr Gastroenterol Rep 2008, 10:316-323.
• [5]Abraham C, Cho JH: Inflammatory bowel disease. N Engl J Med 2009, 361:2066-2078.
• [6]Lloyd-Still JD: Crohn's disease and cystic fibrosis. Dig Dis Sci 1994, 39:880-885.
• [7]Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001, 96:730-734.
• [8]Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A: Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004, 99:2235-2241.
• [9]Feizi T: Carbohydrate-mediated recognition systems in innate immunity. Immunol Rev 2000, 173:79-88.
• [10]Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, et al.: Antibodies against laminaribioside and chitobioside are novel serologic markers in crohn's disease. Gastroenterology 2006, 131:366-378.
• [11]Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, et al.: New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403.
• [12]Simondi D, Mengozzi G, Betteto S, Bonardi R, Ghignone RP, Fagoonee S, et al.: Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:645-651.
• [13]Condino AA, Hoffenberg EJ, Accurso F, Penvari C, Anthony M, Gralla J, et al.: Frequency of ASCA seropositivity in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005, 41:23-26.
• [14]Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B: Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997, 145:794-803.
• [15]Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, et al.: New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008, 103:665-681.
• [16]Henckaerts L, Pierik M, Joossens M, Ferrante M, Rutgeerts P, Vermeire S: Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007, 56:1536-1542.
• [17]Lachenal F, Nkana K, Nove-Josserand R, Fabien N, Durieu I: Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis. Eur Respir J 2009, 34:1079-1085.
• [18]Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, et al.: Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996, 110:1810-1819.
• [19]Harrer M, Reinisch W, Dejaco C, Kratzer V, Gmeiner M, Miehsler W, et al.: Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur J Gastroenterol Hepatol 2003, 15:1281-1285.
• [20]Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, et al.: Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001, 7:8-15.
• [21]Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, et al.: Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005, 54:1232-1236.
• [22]Lindberg E, Magnusson KE, Tysk C, Järnerot G: Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowef disease. Gut 1992, 33:909-913.
• [23]Konrad A, Rütten C, Flogerzi B, Styner M, Göke B, Seibold F: Immune sensitization to yeast antigens in ASCA positive patients with Crohn's disease. Inflamm Bowel Dis 2004, 10:97-105.
• [24]Seibold F, Slametschka D, Gregor M, Weber P: Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994, 107:532-536.
• [25]Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J: Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with crohn's disease. Gut 2000, 46:58-63.
• [26]Leclercq-Foucart J, Forget PP, Van Cutsem JL: Lactulose-rhamnose intestinal permeability in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 1987, 6:66-70.
• [27]Hsieh MC, Berry HK: Protease inhibitor and defective proteolysis in cystic fibrosis. Dig Dis Sci 1988, 33:282-288.
• [28]Slomiany A, Liau YH, Carter SR, Newman LJ, Slomiany BL: Mucus glycoprotein fatty acyltransferase in patients with cystic fibrosis: effect on the glycoprotein viscosity. Biochem Biophys Res Commun 1985, 132:299-306.
• [29]Clarke LL, Gawenis LR, Bradford EM, Judd LM, Boyle KT, Simpson JE, et al.: Abnormal Paneth cell granule dissolution and compromised resistance to bacterial colonization in the intestine of CF mice. Am J Physiol Gastrointest Liver Physiol 2004, 286:G1050-1058.
• [30]Wehkamp J, Harder J, Weichenthal M, Schwab M, Schäffeler E, Schlee M, et al.: NOD2 (CARD15) mutations in crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004, 53:1658-1664.